High-dose insulin euglycaemic therapy (HIET): How high is high enough and what are the risks?

Authors

A Dos Santos, S Feris, Z Farina

Published in

The Southern African journal of critical care : the official journal of the Critical Care Society. Volume 42. Issue 1. Pages e3800. Epub Apr 23, 2026.

Abstract

Calcium-channel blockers (CCBs) are widely prescribed in South Africa and are frequently implicated in overdose-related morbidity and mortality. We report a case of amlodipine overdose in a teenager. Her management is notable for the exceptionally high dose of insulin used as part of high dose insulin euglycaemic therapy (HIET), far exceeding standard protocol. Despite the aggressive dosing, no clinically significant hypoglycaemia or hypokalaemia occurred. The patient showed progressive improvement and was discharged from the intensive care unit on day 3, making a full recovery. This case demonstrates that insulin doses significantly exceeding conventional protocols may be safe and effective in resource-limited settings when supported by experienced staff and close monitoring. More research is needed to guide optimal HIET dosing and safe discontinuation protocols.
This case demonstrates that concentrated insulin formulations, combined with appropriate monitoring and level of care, can safely deliver higher than usual insulin doses. The use of concentrated insulin significantly reduces its contribution to total fluid administration, providing a practical approach to fluid stewardship. The report highlights a clinical management gap: the absence of standardised protocols for discontinuing insulin and dextrose infusions after high-dose insulin euglycaemic therapy. This case provides data on successful weaning and cessation of HIE and dextrose therapy following unconventionally high insulin dosing. High insulin doses may warrant consideration in severe calcium channel blocker toxicity when conventional haemodynamic support is unavailable or deemed insufficient.

PMID:
42416000
Bibliographic data and abstract were imported from PubMed on 08 Jul 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.